Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

Janne, PA; Baik, C; Su, WC; Johnson, ML; Hayashi, H; Nishio, M; Kim, DW; Koczywas, M; Gold, KA; Steuer, CE; Murakami, H; Yang, JCH; Kim, SW; Vigliotti, M; Shi, R; Qi, ZH; Qiu, Y; Zhao, LH; Sternberg, D; Yu, CN; Yu, HA

Janne, PA (通讯作者)，Dana Farber Canc Inst, 450 Brookline Ave,LC4114, Boston, MA 02115 USA.

CANCER DISCOVERY, 2022; 12 (1): 74

Abstract

Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索